Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients

BACKGROUND: Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence of circulating ESR1 mutations at the end of adjuvant treatment by AI in early breast cancer had never been clearly established....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Allouchery, Violette, Beaussire, Ludivine, Perdrix, Anne, Sefrioui, David, Augusto, Laetitia, Guillemet, Cécile, Sarafan-Vasseur, Nasrin, Di Fiore, Frédéric, Clatot, Florian
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5956618/
https://ncbi.nlm.nih.gov/pubmed/29769099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-018-0968-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars